Literature DB >> 8160466

Why are low-density lipoproteins atherogenic?

S G Young1, S Parthasarathy.   

Abstract

Low-density lipoproteins (LDLs) carry most of the cholesterol in human plasma, and high levels of LDL cholesterol clearly cause heart disease. In recent years, many scientists have focused on elucidating the pathophysiologic steps that lie between elevated levels of LDL in the plasma and atherosclerotic plaques in the arterial wall. A large number of scientific studies indicate that oxidation of LDL within the arterial wall may be an important early step in atherogenesis. The uptake of oxidized LDL by macrophages is a likely explanation for the formation of macrophage foam cells in early atherosclerotic lesions. In addition, oxidized LDL has many other potentially proatherogenic properties.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8160466      PMCID: PMC1022322     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  107 in total

Review 1.  The value of lowering cholesterol after myocardial infarction.

Authors:  J E Rossouw; B Lewis; B M Rifkind
Journal:  N Engl J Med       Date:  1990-10-18       Impact factor: 91.245

Review 2.  Oxidative modification of LDL: comparison between cell-mediated and copper-mediated modification.

Authors:  S Parthasarathy; L G Fong; M T Quinn; D Steinberg
Journal:  Eur Heart J       Date:  1990-08       Impact factor: 29.983

3.  Expression of the acetyl low density lipoprotein receptor by rabbit fibroblasts and smooth muscle cells. Up-regulation by phorbol esters.

Authors:  R E Pitas
Journal:  J Biol Chem       Date:  1990-07-25       Impact factor: 5.157

4.  Minimally modified low density lipoprotein stimulates monocyte endothelial interactions.

Authors:  J A Berliner; M C Territo; A Sevanian; S Ramin; J A Kim; B Bamshad; M Esterson; A M Fogelman
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

5.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

Authors:  J P Kane; M J Malloy; T A Ports; N R Phillips; J C Diehl; R J Havel
Journal:  JAMA       Date:  1990-12-19       Impact factor: 56.272

6.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

7.  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)

Authors:  H Buchwald; R L Varco; J P Matts; J M Long; L L Fitch; G S Campbell; M B Pearce; A E Yellin; W A Edmiston; R D Smink
Journal:  N Engl J Med       Date:  1990-10-04       Impact factor: 91.245

8.  Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells.

Authors:  S D Cushing; J A Berliner; A J Valente; M C Territo; M Navab; F Parhami; R Gerrity; C J Schwartz; A M Fogelman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

9.  Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis.

Authors:  S Parthasarathy; J C Khoo; E Miller; J Barnett; J L Witztum; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 10.  Recent progress in understanding apolipoprotein B.

Authors:  S G Young
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

View more
  12 in total

Review 1.  Oxidative stress in cardiovascular disease.

Authors:  S Parthasarathy; N Khan-Merchant; M Penumetcha; N Santanam
Journal:  J Nucl Cardiol       Date:  2001 May-Jun       Impact factor: 5.952

Review 2.  Molecular link between cholesterol, cytokines and atherosclerosis.

Authors:  D Kaul
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

3.  Low-density lipoprotein oxidation and the pathogenesis of atherosclerosis.

Authors:  A Chait
Journal:  West J Med       Date:  1994-02

4.  A Novel Mechanism for Atherosclerotic Calcification: Potential Resolution of the Oxidation Paradox.

Authors:  Aladdin Riad; Chandrakala Aluganti Narasimhulu; Pragney Deme; Sampath Parthasarathy
Journal:  Antioxid Redox Signal       Date:  2018-01-24       Impact factor: 8.401

5.  The effect of Beta glucan on Cisplatin ototoxicity.

Authors:  Tuba Bayindir; Mustafa Iraz; Mehmet Kelles; Serdar Kaya; Mehmet Tan; Aliye Filiz; Yuksel Toplu; M Tayyar Kalcioglu
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2013-02-06

Review 6.  Why fish oil fails: a comprehensive 21st century lipids-based physiologic analysis.

Authors:  B S Peskin
Journal:  J Lipids       Date:  2014-01-16

7.  Effects of patient-tailored atorvastatin therapy on ameliorating the levels of atherogenic lipids and inflammation beyond lowering low-density lipoprotein cholesterol in patients with type 2 diabetes.

Authors:  Jang Won Son; Dong Jun Kim; Chang Beom Lee; Seungjoon Oh; Kee-Ho Song; Chan Hee Jung; Ji Oh Mok; Jong Hwa Kim; Min Kyong Moon; Kyung Mook Choi; Jae Hyoung Cho; Sung Hee Choi; Soo Kyung Kim; Kang Seo Park; Hye Soon Kim; In Joo Kim; Young Il Kim; Hae Jin Kim; Sang Yong Kim; Sungrae Kim
Journal:  J Diabetes Investig       Date:  2013-03-26       Impact factor: 4.232

8.  Evaluation of the protective effect of Beta glucan on amikacin ototoxicity using distortion product otoacoustic emission measurements in rats.

Authors:  Tuba Bayindir; Aliye Filiz; Mustafa Iraz; Serdar Kaya; Mehmet Tan; Mahmut Tayyar Kalcioglu
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-03-08       Impact factor: 3.372

9.  Serum myeloperoxidase activity, total antioxidant capacity and nitric oxide levels in patients with chronic otitis media.

Authors:  Mehmet Fatih Garça; Mehmet Aslan; Bakır Tuna; Ahmet Kozan; Hakan Cankaya
Journal:  J Membr Biol       Date:  2013-06-12       Impact factor: 1.843

Review 10.  Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.